Insider trade

Coherus Oncology (CHRS): Director received 30K shares

Rita A Karachun, Director at Coherus Oncology, reported a grant / award of 30K shares.

30K
Shares
Traded
Jun 5, 2026
Filed
Jun 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 11, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Jun 12, 2026Company filing · Form 8-K · Auditor changeChanged its auditor“On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date.”
  2. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
  3. Aug 17, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Coherus Oncology

OQRO holds no insider, Congress, fund or contract record for Coherus Oncology dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CHRS page.

How this filing works

Explore the data

Common questions

Which Coherus Oncology (CHRS) insider traded, and how much?

Rita A Karachun, Director at Coherus Oncology, reported a grant / award of 30K shares. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jun 5, 2026. Filed: Jun 9, 2026. That is 4 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean CHRS stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Coherus Oncology

Everything OQRO holds on this company is on its CHRS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data